SCHEMBL3894147

SCHEMBL3894147

CCCC(C1=CCC(N)C1)[P@@H](=O)O

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GABBR1 Q9UBS5 3/20 0.36
GABRR1 P24046 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585708 0.76
SCHEMBL3892898 0.76 GABBR1 (0.41) GABBR1GABRR1
SCHEMBL4586827 0.71
SCHEMBL3893304 0.70
SCHEMBL3898970 0.67 GABRR1 (0.38) GABBR1GABRR1
SCHEMBL3896387 0.62 OAT (0.31)
SCHEMBL4252850 0.62
SCHEMBL7925354 0.61 AOC3 (0.43)
SCHEMBL3894228 0.61 GABRR1 (0.41) GABBR1GABRR1
SCHEMBL3897692 0.61 GABRR1 (0.41) GABBR1GABRR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038464-A1 METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2015-02-05 US disclosed
EP-1773740-B1 NEUROLOGICALLY-ACTIVE COMPOUNDS UNIV SYDNEY (AU) 2009-02-18 EP disclosed
US-20080032950-A1 Neurologically-Active Compounds THE UNIVERSITY OF SYDNEY (AU) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038464-A1 METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION GRM5, GRM1, GRIK5 GABBR1 26/4885GABRR1 47/4885
US-20080032950-A1 Neurologically-Active Compounds GABRE, GABRA5, GABRA1 GABBR1 20/4885GABRR1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.